Stockholm3 prostate cancer test (coming soon)
Stockholm3 is a blood test that goes beyond PSA to assess your risk of clinically significant prostate cancer. By combining several blood markers with genetic information and clinical detail, it gives a far more precise picture of your risk – helping find the cancers that matter, while sparing many men from unnecessary investigation. Preologi provides clinician-led access to the test, including interpretation of your result and support with any next steps.
More than a PSA test
For years, PSA has been the main blood test used to assess prostate cancer risk – but it has real limitations. PSA is produced by healthy as well as cancerous prostate tissue, and can be raised by benign enlargement, inflammation and other non-cancerous conditions. At the same time, some important cancers occur without a markedly raised PSA. Stockholm3 is different. Rather than relying on PSA alone, it combines PSA with additional protein markers, genetic markers and clinical information such as age and family history. An algorithm then calculates your individual probability of having clinically significant prostate cancer. It is a risk-assessment tool, not a diagnosis.
- Protein markers – PSA plus additional prostate-related proteins, for a fuller biochemical picture
- Genetic markers – inherited genetic information linked to prostate cancer risk
- Clinical information – factors such as age and family history
- One risk score – an algorithm combines these into your personal probability of clinically significant disease
Who should consider the Stockholm3 test?
Stockholm3 is principally validated for men aged 45 to 74, particularly those with a PSA of 1.5 ng/mL or above. It may suit men who want a clearer assessment of their prostate cancer risk, those with a family history of prostate cancer, or anyone weighing up whether further investigation is needed. A Preologi clinician will review your history and results before confirming whether the test, and any next steps, are right for you.
Clearer answers, fewer unnecessary procedures
Assessing risk more precisely means significant cancers can be identified sooner, while men at low risk are spared invasive tests they don’t need. In the original STHLM3 study of almost 59,000 men, Stockholm3 was considerably better than PSA alone at telling clinically significant prostate cancer apart from low-risk or benign disease – and at the same level of cancer detection as PSA, it could reduce the number of biopsies by around a third.
Understanding what the results can and cannot tell you
Stockholm3 is a risk-assessment test, not a diagnosis. An elevated result means further assessment is recommended, not that cancer is present.
A clinician will confirm whether the test is suitable for you
Suitability – including the right PSA context – is confirmed individually by a Preologi clinician.
Simple, clear and guided by experts
Book your test
Our team will review your information, confirm your eligibility and explain the process before you proceed
Provide a blood sample
A trained phlebotomist takes a routine blood sample at a Preologi clinic or approved partner. No fasting is required, and the appointment usually takes 15 to 20 minutes
Laboratory analysis
Your sample is analysed and the results combined with your clinical information to calculate your personal risk score
Receive your result
A qualified clinician explains your risk score clearly, answers your questions and talks you through any recommended next steps
Follow-up support
If your result is elevated, Preologi helps coordinate specialist urological assessment and multiparametric MRI, reserving biopsy for those who need it
Your result, explained by a clinician
Lower-risk result (below the referral threshold)
Your calculated risk of clinically significant prostate cancer is low. This can be reassuring, but it does not rule out cancer entirely. Your clinician will advise on routine monitoring and when to retest
Elevated result (at or above the referral threshold)
Your calculated risk is higher, and specialist assessment is recommended. This is not a diagnosis – it means further investigation, usually an MRI, is the right next step
Whatever your result, you are supported
Preologi’s clinical team will explain your result and the appropriate next steps. When a result is elevated, we help coordinate specialist urological assessment and multiparametric MRI promptly, so that invasive biopsy is reserved for the men who genuinely need it. Our aim is to make sure you understand what your result means, what it does not mean, and what to do next.
Two tests, a clearer picture
Stockholm3 and the Galleri® test look for prostate cancer in very different ways, and can work together. Stockholm3 gives a sensitive, prostate-specific assessment of your risk. Galleri® looks for a cancer signal across more than 50 cancer types and, when it does detect prostate cancer, tends to flag the more aggressive disease. Taken together from a single blood collection, they can provide complementary information – helping identify the men who would benefit from imaging, while keeping unnecessary investigation to a minimum.
Answers to common questions
PSA measures a single protein that can be raised for many non-cancer reasons. Stockholm3 combines PSA with additional protein and genetic markers and clinical information to calculate your individual risk of significant prostate cancer – a more precise assessment
No. It assesses risk. An elevated result means further investigation is recommended, not that cancer is present
A clinician explains your result and helps arrange specialist assessment, usually including an MRI, with a biopsy only if it’s needed
Principally men aged 45 to 74, particularly those with a PSA of 1.5 ng/mL or above. A clinician confirms suitability
Yes. The two can be run from a single blood collection and provide complementary information. Your clinician can advise
Important Safety Information
tbc
Laboratory/Test Information
tbc